Clinical Trials in Crystal Arthropathy

Rheumatic Disease Clinics of North America

Volumn 32, Issue 2, 2006, Pages 359-382

  Joseph Ridge, Nancy ^a   Cazzetta, Susan ^a,b   MacDonald, Patricia ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CYANO 4 NEOPENTYLOXYPHENYL)PYRAZOLE 4 CARBOXYLIC ACID; 6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE; ALLOPURINOL; ANTIGOUT AGENT; AZAPROPAZONE; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; DICLOFENAC; ETANERCEPT; ETODOLAC; ETORICOXIB; FEBUXOSTAT; FENOFIBRATE; FLURBIPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; KETOROLAC; LOSARTAN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PROBENECID; RASBURICASE; ROFECOXIB; SCOPOLETIN; TENOXICAM; UNCLASSIFIED DRUG; URATE OXIDASE; Y 700;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRITIS; ARTHROPATHY; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEMOLYSIS; HEPATITIS; HUMAN; HYPERURICEMIA; LIVER TOXICITY; METHEMOGLOBINEMIA; MULTICENTER STUDY; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOGOUT; REVIEW; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ACUTE DISEASE; CLINICAL TRIALS; GOUT; HUMANS; MEDLINE;

EID: 33646568803     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.02.002     Document Type: Review

References (143)

1. McCarty D.J. Crystals and arthritis. Dis Mon 40 (1994) 255-299
2. McGill N.W. Gout and other crystal-associated arthropathies. Baillieres Clin Rheumatol 14 (2000) 445-460
3. Wortmann R.L., and Kelley W.N. Gout and hyperuricemia. In: Reddy C., Harris D., Sledge M., et al. (Eds). Kelley's textbook of rheumatology (2005), Elsevier Saunders, Philadelphia 1402-1429
4. Rosenthal A.K., and Ryan L.M. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 21 (1995) 151-161
5. Schumacher H.R. Crystal-induced arthritis: an overview. Am J Med 100 2A (1996) 46S-52S
6. Abramson S.B. Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 4 (1992) 295-300
7. Wortmann R.L. Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field. Curr Rheumatol Rep 6 (2004) 235-239
8. Pawlotsky Y. What is the optimal treatment for acute crystal-induced arthritis?. Rev Rheum [English edition] 63 (1996) 231-233
9. Meyers O.L., Cassim B., and Mody G.M. Hyperuricaemia and gout: clinical guidelines 2003. S Afr Med J 93 (2003) 961-971
10. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64 (2004) 2399-2416
11. Dorfler H. Therapie des akuten gichtanfalls mit acemetacin. Therapiewock 35 (1985) 1161-1166
12. Franck W.A., and Brown M.M. Ibuprofen in acute polyarticular gout [letter]. Arthritis Rheum 19 (1976) 269
13. Schweitz M.C., Nashel D.J., and Alepa P. Ibuprofen in the treatment of acute gouty arthritis. JAMA 239 (1978) 34-35
14. Smyth C.J., and Percy J.S. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 29 (1973) 82-87
15. Polderman J., and Colon M. Oxamethacin: a pilot field survey. J Int Med Res 7 (1979) 83-89
16. Ruosti A., and Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial. Scand J Rheumatol Suppl 21 (1978) 15-17
17. Lomen P.L., Turner L.F., Lamborn K.R., et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 80 (1986) 134-139
18. Altman R.D., Honig S., Levin J.M., et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 15 (1988) 1422-1426
19. Fraser R.C., Davis R.H., and Walker F.S. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia. J R Coll Gen Pract 37 (1987) 409-411
20. Eberl R., and Dunky A. Meclofenomate sodium in the treatment of acute gout. Arzneimittelforschung 33 (1983) 641-643
21. Weiner G.L., White S.R., Weitzner R.I., et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 22 (1979) 425-426
22. Wanasukapent S., Lertratenakul Y., and Rubinstein H.M. Effect of fenoprofen calcium on acute gouty arthritis. Arthritis Rheum 19 (1976) 933-935
23. Garcia de la Torre I. Estudio doble-ciego paralelo, comparativo con tenaxicam vs placebo en artritis gotosa aguda [Double-blind parallel-study comparin tenoxicam and placebo in acute gouty arthritis]. Invest Med Int 14 (1987) 92-97 [in Spanish]
24. Karachalios G.N., and Donas G. Sulindac in the treatment of acute gouty arthritis. Int J Tiss Res 4 (1982) 297-299
25. Cheng T.T., Lai H.M., Chiu C.K., et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 26 (2004) 399-406
26. Rubin B.R., Burton R., Navarra S., et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 50 (2004) 598-606
27. Schumacher H.R., Boice J.A., Daikh D.I., et al. Randomized double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 324 (2002) 1488-1492
28. Shrestha M., Chiu M.J., Martin R.I., et al. Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine. Am J Emerg Med 12 (1994) 454-455
29. Strestha M., Morgan D.L., Moreden J.M., et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 26 (1995) 682-686
30. Lederman R. A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Adv Ther 7 (1990) 344-354
31. Maccagno A., Di Giorgio E., and Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 12 (1991) 423-429
32. Alvarellos A., and Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 13 (1986) 804-806
33. Ahern M.J., Reid C., Gordon T.P., et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17 (1987) 301-304
34. Harris C.M., Siegel L.B., and Alloway J.A. Gout and hyperuricemia. Am Fam Physician 59 (1999) 925-934
35. Hollander J.L. Intra-articular hydrocortisone in the treatment of arthritis. Ann Intern Med 39 (1953) 735-746
36. Hollander J.L., Jessar R.A., and Brown Jr. E.M. Intra-articular corticosteroid therapy. Am Pract 12 (1961) 190-193
37. Hollander J.L. Current concepts of pathogenesis of rheumatoid arthritis. Del Med J 41 (1969) 65-66
38. Gray R.G., Tenebaum J., and Gottlieb N.L. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 10 (1981) 231-254
39. Gray R.G., and Gottlieb N.L. Intra-articular corticosteroids: an updated assessment. Clin Orthop 177 (1983) 235-263
40. Groff G.D., Franck W.A., and Raddatz D.A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 19 (1990) 329-336
41. Werlen D., Gabay C., and Vischer T.L. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal anti-inflammatory drugs. Rev Rhum 63 (1996) 248-254
42. Roane D.W., Harris M.D., Carpenter M.T., et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol 150 (1997) 677-683
43. Alloway J.A., Moriaty M.J., Hoogland Y.T., et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 20 (1993) 111-113
44. Axelrod D., and Preston S. Comparison of parenteral adrenocrticostropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 31 (1988) 803-805
45. Wolfson W.Q., Cohn C., and Levine R. Rapid treatment of acute gouty arthritis by concurrent administration of pituitary adrenocorticotropic hormone (ACTH) and colchicine. J Lab Clin Med 34 (1949) 1766
46. Muzzolini M., Rosetto G., and Compagnoni A. Terapia dell'attacco gottoso con ACTH sinetico ad azione ritardata [Therapy of gout attacks with synthetic delayed-action ACTH]. Policlinico [Med] 77 (1970) 322-332 [in Italian]
47. Ritter J., Kerr L.D., Valeriano-Marcet J., et al. ACTH revisited: effective treatment of acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 21 (1994) 696-699
48. Ritter J.M., Kerr L.D., Valeriano-Marcet J., et al. The use of parenteral ACTH for acute crystal-induced synovitis in patients with multiple medical problems. Arthritis Rheum 35 (1992) S225-S228
49. Taylor C.T., Brooks N.C., and Kelley K.W. Corticotropin for acute management of gout. Ann Pharmacother 35 (2001) 365-368
50. Siegel L.B., Alloway J.A., and Nashel D.J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 21 (1994) 1325-1327
51. Kim K.Y., Schumacher H.R., Hunsche E., et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 25 (2003) 1593-1617
52. Tausche A.K., Richter K., Grassler A., et al. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63 (2004) 1351-1352
53. Fiehn C., Wunder A., Krienke S., et al. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int 25 (2005) 108-113
54. Yu T.F., and Gutman A.B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 55 (1961) 179-192
55. Yu T.F. The efficacy of colchicine prophylaxis in articular gout-a reappraisal after 20 years. Semin Arthritis Rheum 12 (1982) 256-264
56. Li-Yu J., Clayburne G., Sieck M., et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol 28 (2001) 577-580
57. Paulus H.E., Schlosstein L.H., Godfrey R.G., et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 17 (1974) 609-614
58. Borstad G.C., Bryant L.R., Abel M.P., et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31 (2004) 2429-2432
59. Das S.K., Ramakrishnan S., Mishra K., et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of colchicine in osteoarthritis of the knee. A preliminary report. Arthritis Rheum 47 (2002) 280-284
60. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52 (2005) 916-923
61. Wortmann R., Becker M.A., Schumacher H.R., et al. Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Arthritis Rheum 50 (2004) S335-S336
62. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353 (2005) 2450-2461
63. Gast L.F. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 6 (1987) 70-73
64. Van Lieshout-Zuidema M.F., and Breedveld F.C. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 20 (1993) 1383-1385
65. Bull P.W., and Scott J.T. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 16 (1989) 1246-1248
66. Perez-Ruiz F., Calabozo M., Pijoan J.I., et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47 (2002) 356-360
67. Perez-Ruiz F.D., Also-Ruiz A., Calabozo M., et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57 (1998) 545-549
68. Shoji A., Yamanaka H., and Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51 (2004) 321-325
69. Bishop C., Rand R., and Talbott J.H. Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest 30 (1951) 889-895
70. Scott J.T. Comparison of allopurinol to probenecid. Ann Rheum Dis 25 (1966) 623-626
71. Conaghan P.G., and Day R.O. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf 11 (1994) 252-258
72. Spieker L.E., Ruschitzka F.T., Lüscher T.F., et al. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 4 (2002) 403-410
73. Schepers G.W. Benzbromarone therapy in hyperuricaemia: comparison with allopurinol and probenecid. J Int Med Res 9 (1981) 511-515
74. Arntz H.R., Dreykluft H.R., and Leonardt H. Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study. Fortschr Med 97 (1979) 1212-1214
75. Berg H. Effectiveness and tolerance of long-erm uricosuric treatment. Z Gesamte Inn Med 45 (1990) 719-720
76. van der Klauw M.M., Houtman P.M., Stricker B.H., et al. Hepatic injury caused by benzbromarone. J Hepatol 20 (1994) 376-379
77. Gehenot M., Horsmans Y., Rahier J., et al. Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol 20 (1994) 842
78. Hautekeete M.L., Henrion J., Naegels S., et al. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver 15 (1995) 25-29
79. Bellamy N., Brooks P.M., Emmerson B.T., et al. A survey of the current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 151 (1989) 535-537
80. Weinberger A., and Pinkhas J. The efficacy of treatment with allopurinol versus uricosuric drugs in gout. Panminerva Med 20 (1978) 155-156
81. Rundles R.W., Metz E.N., and Silberman H.R. Allopurinol in the treatment of gout. Ann Intern Med 64 (1966) 229-258
82. Beutler A.M., Rull M., Schlesinger N., et al. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid [letter]. Clin Exp Rheumatol 19 (2001) 595
83. Wolf F., and Cathey M.A. The misdiagnosis of gout and hyperuricemia. J Rheumatol 18 (1991) 1232-1234
84. Bellamy N., Gilbert J.R., Brooks P.M., et al. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol 15 (1988) 1841-1847
85. Beutler A.M., Rull M., Schleschinger N., et al. Allopurinol may have protective effect against acute gouty arthritis independent from its hypouricemic action. Arthritis Rheum 39 Suppl (1996) S86
86. Arellano F., and Sacristan J.A. Allopurinol hypersensitivity syndrome. A review. Ann Pharmacother 27 (1993) 337-343
87. Singer J.Z., and Wallace S.L. The allopurinol hypersensitivity syndrome, unnecessary morbidity and mortality. Arthritis Rheum 29 (1986) 82
88. Hande K.R., Noone R.M., and Stone W.J. Severe allopurinol toxicity: description and guidelines for prescription in patients with renal insufficiency. Am J Med 76 (1984) 47-56
89. Adriani J., and Naraghi M. Allopurinol: actions, adverse reactions, and drug interaction. Intern Med 6 (1985) 114
90. Young J.L., Boswell R.B., and Nies A.S. Severe allopurinol hypersensitivity syndrome. Association with thiazides and prior renal compromise. Arch Intern Med 134 (1974) 553-558
91. Lupton G.P., and Odom R.B. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1 (1979) 365-374
92. Bieber J.D., and Terkeltaub R.A. Gout: on the brinkof novel therapeutic options for an ancient disease. Arthritis Rheum 50 (2004) 2400-2414
93. Fam A.G., Dunne S.M., Iazzetta J., and Paton T.W. Efficacy and safety of desenstization to allopurinol following cutaneous reactions. Arthritis Rheum 44 (2001) 231-238
94. Lockard O., Harmon C., Nolph K., et al. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 85 (1976) 333-335
95. Walter-Sack I., de Vries J.X., Kutschker C., et al. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur J Clin Pharmacol 49 (1995) 215-220
96. FDA Advisory Committee 2004. Available at:. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4044b1.htm Accessed September 23, 2005
97. Okamoto K., Eger B.T., Nishino T., et al. An extremely potent inhibitor of xanthine oxidoreductase. J Biol Chem 278 (2003) 1848-1855
98. Takano Y., Hase-Aoki K., Horiuchi H., et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76 (2005) 1835-1847
99. Horiuchi H., Ota M., Kobayashi M., et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 104 (1999) 307-319
100. Osada Y., Tsuchimoto M., Fukushima H., et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 241 (1993) 183-188
101. Becker M.A., Kisicki J., Khosravan R., et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 23 (2004) 35-40
102. Horiuchi H., Ota M., Nishimura S.-I., et al. Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 66 (2000) 2051-2070
103. Nishida Y., Kamatani N., Tanimoto K., et al. Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside. Agents Actions 9 (1979) 549-552
104. Yamamoto T., Moriwaki Y., Fuimura Y., et al. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 60 (2000) 34-40
105. Mayer M.D., Khosravan R., Vernillet L., et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12 (2005) 22-34
106. Hoshide S., Takahashi Y., Ishikawa T., et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 23 (2004) 1117-1118
107. Khosravan R., Grabowski B.A., Mayer M.D., et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase. J Clin Pharmacol 46 (2006) 88-102
108. Schumacher H.R., Wortmann R., Becker M.A., et al. A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase [abstract]. Arthritis Rheum 50 9 Suppl (2004) S335
109. Schumacher H.R., Becker M.A., Wortmann R.L., et al. Febuxostat vs. Allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthritis Rheum 52 (2005) S680
110. Kamantani N., Fujimori S.H., Hada T., et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia [abstract]. Arthritis Rheum 48 9 Suppl (2003) S530
111. Kamatani N., Fujimori S., Hada T., et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia [abstract]. Arthritis Rheum 50 9 Suppl (2004) S337
112. Kamatani N., Fujimori S., Hada T., et al. Febuxostat, a novel non-purine selective inhibitor of xanthine-oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia [abstract]. Arthritis Rheum 50 9 Suppl (2004) S336-S337
113. Pui C.H. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 3 (2002) 433-442
114. Davidson M.B., Thakkar S., Hix J.K., et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116 (2004) 546-554
115. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 20 (2005) 431-433
116. Goldman S.C., Holcenberg J.S., Finklestein J.Z., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97 (2001) 2998-3003
117. Pui C.H., Mahmoud H.H., Wiley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19 (2001) 697-704
118. Pui C.H., Jeha S., Irwin D., et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15 (2001) 1505-1509
119. Bomalaski J.S., Holtsberg F.W., Ensor C.M., et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 29 (2002) 1942-1949
120. Kelly S.J., Delnomdedieu M., Oliverio M.I., et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12 (2001) 1001-1009
121. FDA Office of Orphan Products Development. Pegylated recombinant mammalian uricase (PEG-uricase) as treatment for refractory gout. Available at:. www.clinicaltrials.gov/ct/show/NCT00111657 Accessed May 31, 2005
122. Chua C.C., Greenberg M.L., Viau A.T., et al. Use of polyethylene glycol-modified uricase (PED-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 109 (1988) 114-117
123. Bomalaski J.S., and Clark M.A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 6 (2004) 240-247
124. Savient Pharmaceuticals Inc. Patient dosing in phase 2 clinical trial of puricase for severe gout completed. 12 Jan 2005. Available at:. www.pharma-lexicon.com/medicalnews.php?newsid=18815 Accessed May 31, 2005
125. Hepburn A.I., Kaye S.A., and Feher M.D. Fenofibrate; a new treatment for hyperuricemia and gout?. Ann Rheum Dis 60 (2001) 984-985
126. Yamamoto T., Moriwaki Y., Takahashi S., et al. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 28 (2001) 2294-2297
127. Takahashi S., Moriwaki Y., Yamamoto T., et al. Effects of combination treatment using anti-hyperuricemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 62 (2003) 572-575
128. Feher M.D., Hepburn A.L., Hogarth M.B., et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout. Rheumatol 42 (2003) 321-325
129. Wortmann R.L. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 17 (2005) 319-324
130. Sica D.A., and Schoolwerth A.C. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 11 (2002) 475-482
131. Ohnishi K., Kohno M., Yukiiri K., et al. Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker. Int J Clin Pharmacol Ther 39 (2001) 417-422
132. Kamper A.L., and Nielsen A.H. Uricosuric effect of losartan in patients with renal transplants. Transplantation 72 (2001) 671-674
133. Minghelli G., Seydoux C., Goy J.J., et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 66 (1998) 268-271
134. Høleggen A., Alderman M.H., Kjedsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 (2004) 1041-1049
135. Niskanen L.K., Laaksonen D.E., Nyyssonen K., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164 (2004) 1546-1551
136. Bengtsson C., Lapidus L., Stendahl C., et al. Hyperuricemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 224 (1988) 549-555
137. Lehto S., Niskanen L., Ronnomaa T., et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29 (1998) 635-639
138. Yamada H., Kotaki H., Furitsu H., et al. Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia. Biopharm Drug Dispos 20 (1999) 77-83
139. Isibuchi S., Morimoto H., Oe T., et al. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 11 (2001) 879-882
140. Yamada I., Fukunari A., Osajima T., et al. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids 23 (2004) 1123-1125
141. Osajima T., Kamezawa M., Fukunari A., et al. Pharmacokinetics and pharmacodynamics of Y-700, a potent and non-renal excretion type of xanthine oxidase inhibitor, in healthy male volunteers. Arthritis Rheum 48 Suppl (2003) S530
142. Noma S., Verho M., Iwane I., et al. Safety, tolerability, pharmacokinetics and lowering uric acid effect of repeated daily dosing with Y-700, a novel xanthine oxidase inhibitor, in healthy male volunteers. Arthritis Rheum 48 Suppl (2003) S530
143. Ding Z., Dai Y., and Wang Z. Hypouricemic action of scopoletin arising from xanthine oxidase inhibition and uricosuric activity. Planta Med 71 (2005) 183-185